Uncategorized

While the extra time to comply is aimed at preventing medical device shortages, the rules have still left some device makers and certifying bodies unclear about how to proceed, says one attorney.

Una investigación reciente ha analizado los servicios de interacciones falsas en las redes sociales. Además de catalogar el ecosistema fraudulento de “likes”, reproducciones, seguidores o visitas online, el estudio señala los modelos económicos que lo sustenta …

Voyager Therapeutics unlocked a potential $600 million plus $25 million upfront as Novartis exercised its option to leverage the company’s capsids against two undisclosed neurologic disease targets.

The transcatheter repair clip beat the established medical therapy on the primary composite endpoint, setting up a battle with a rival company for a $5 billion market.

Follow along as BioSpace keeps you up-to-date on which companies are tightening their belts and cutting staff throughout 2023.  

The FDA set a decision date of July 6, 2023 for Eisai and Biogen’s recently approved Alzheimer’s drug, Leqembi, Eisai announced Monday.

With the results from the CLEAR outcomes study, Esperion is poised for a major inflection in sales and is targeting blockbuster status, said CEO Sheldon Koenig on an investor call Monday.

Here are some tips to help you nail virtual interviews and networking events so you can be prepared for BioSpace’s Virtual Talent Connect on March 9.

Incyte Corporation’s Phase III LIMBER-304 clinical trial has come to an end following a third-party investigation that forecasted poor results.

Manuel García Viejo, director médico de un hosipital de la orden San Juan de Dios, será trasladado a Madrid en un avión militar medicalizado.